Show simple item record

IDIOPATHIC INFLAMMATORY MYOPATHIES. A REVIEW

Miopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejo

dc.contributoren-US
dc.contributores-ES
dc.creatorAcosta, Ignacio; Clínica Alemana Santiago -Universidad del Desarrollo
dc.creatorMatamala, José Manuel; Departamento Neurología y Psiquiatría, Clínica Alemana de Santiago-Universidad del Desarrollo, Santiago, Chile Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile Instituto Milenio de Neurociencia Biomédica (BNI), Facultad de Medicina, Universidad de Chile, Santiago, Chile
dc.creatorJara, Paula; Departamento Neurología y Psiquiatría, Clínica Alemana de Santiago-Universidad del Desarrollo, Santiago, Chile.
dc.creatorPino, Francisca; Departamento Neurología y Psiquiatría, Clínica Alemana de Santiago-Universidad del Desarrollo, Santiago, Chile.
dc.creatorGajardo, Alejandra; Departamento de Anatomía Patológica, Clínica Alemana de Santiago-Universidad del Desarrollo, Santiago, Chile.
dc.creatorVerdugo, Renato; Departamento Neurología y Psiquiatría, Clínica Alemana de Santiago-Universidad del Desarrollo, Santiago, Chile
dc.date2018-12-17
dc.date.accessioned2019-11-11T18:26:45Z
dc.date.available2019-11-11T18:26:45Z
dc.identifierhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/6735
dc.identifier.urihttps://revistaschilenas.uchile.cl/handle/2250/110806
dc.descriptionIdiopathic inflammatory myopathies (IIM) are a heterogeneous group of acquired immune-mediated diseases, which typically involve the striated muscle with a variable involvement of the skin and other organs. Clinically, they are characterized by proximal muscle weakness, elevation of muscle enzymes, myopathic changes on electromyography and an abnormal muscle biopsy. The different IIM have been classified according to their distinctive histopathologic features in dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM) and immune-mediated necrotizing myopathy (IMNM). Several myositis-specific antibodies are associated with the different clinical pictures, as well as with different risk of neoplastic disease and systemic complications. The basis for the treatment of DM, PM, and IMNM is immunosuppression. For IBM there are only symptomatic treatments. Steroids, associated or not with other immunosuppressant drugs, are the first line of treatment. Biologic drugs will allow future individualized therapies. The 10-year survival of DM, PM and IMNM is 62 to 90%. The leading causes of death are neoplastic, lung and cardiac complications. IBM does not impair survival, although it affects the quality of life.en-US
dc.descriptionIdiopathic inflammatory myopathies (IIM) are a heterogeneous group of acquired immune-mediated diseases, which typically involve the striated muscle with a variable involvement of the skin and other organs. Clinically, they are characterized by proximal muscle weakness, elevation of muscle enzymes, myopathic changes on electromyography and an abnormal muscle biopsy. The different IIM have been classified according to their distinctive histopathologic features in dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM) and immune-mediated necrotizing myopathy (IMNM). Several myositis-specific antibodies are associated with the different clinical pictures, as well as with different risk of neoplastic disease and systemic complications. The basis for the treatment of DM, PM, and IMNM is immunosuppression. For IBM there are only symptomatic treatments. Steroids, associated or not with other immunosuppressant drugs, are the first line of treatment. Biologic drugs will allow future individualized therapies. The 10-year survival of DM, PM and IMNM is 62 to 90%. The leading causes of death are neoplastic, lung and cardiac complications. IBM does not impair survival, although it affects the quality of life.es-ES
dc.formatapplication/pdf
dc.languagespa
dc.publisherRevista Médica de Chilees-ES
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/6735/4795
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6735/34682
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6735/35089
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6735/35188
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6735/37544
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6735/37545
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6735/37782
dc.sourceRevista Médica de Chile; Vol. 147, núm. 3 (2019): MARZO 2019es-ES
dc.source0034-9887
dc.subjectDermatomyositis; Inclusion Body; Myositis; Polymyositisen-US
dc.subjectDermatomyositis; Inclusion Body; Myositis; Polymyositises-ES
dc.titleIDIOPATHIC INFLAMMATORY MYOPATHIES. A REVIEWen-US
dc.titleMiopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejoes-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typees-ES


This item appears in the following Collection(s)

Show simple item record